Skip to content

COgnitioN with VERiciGuat Evaluation in Heart Failure

Cognitive Impairment | Heart Failure | Memory Problems

This study, called CONVERGE-HF, is looking at a Health Canada approved drug called Vericiguat to see if it can help people who have heart failure and some memory problems. The study will compare Vericiguat to the usual heart failure medications people get. The researchers want to see how well Vericiguat works by looking at brain and heart images, blood tests, physical and mental abilities, quality of life, and any health problems that come up. Participants will take Vericiguat or the usual treatment for approximately 6 months.

null

Conditions de participation

  • Sexe:

    Any

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:
Age- 18-90 years

Established chronic heart failure (≥6months)

Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).
Exclusion Criteria:
Patients who have contraindications for vericiguat therapy (i.e.use of long- acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding.
Unable to undergo Cardiac Magnetic Resonance Imaging (MRI) or brain MRI, implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias.
General medical conditions:uncontrolled thyroid disorders, liver failure, or recent (previous 3 months) myocardial coronary angioplasty and/or heart surgery, cancer/malignancy, or severe dementia.
Allergies to the study drug.
Currently hospitalized.

Lieu de l'étude

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Quentin Kushnerik

[email protected]
null
Étude parrainée par
University of Alberta
Participants recherchés
Plus d'informations
ID de l'étude: Pro00146022